Allinaire Therapeutics

Pre-clinical

Cambridge, United StatesFounded 2016allinaire.com

Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University. EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. ...

Founded

2016

Focus

AntibodiesBiologics

About

Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University. EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. ...

Funding History

1

Total raised: $8M

Seed$8MUndisclosedMar 15, 2022

Company Info

TypePrivate

Founded2016

LocationCambridge, United States

StagePre-clinical

Contact

Sectors

Biologics / Biosimilars

SIMILAR COMPANIES

BASi Research Products

Pre-clinical · West Lafayette

Bay BioSciences

Pre-clinical · San Francisco

Pre-clinical · Cambridge

Pre-clinical · Memphis

Belcher Pharmaceuticals

Pre-clinical · Miami

Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.